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Abstract: Short-chain mono-alkylphenols provide an example of where a category-approach to 18 
read-across may be used to estimate the repeated-dose endpoint for a number of derivatives. 19 
Specifically, the NOAELs of 50 mg/kg bw/d for mono-methylphenols based on a LOAEL of 20 
very low systemic toxicity can be read across with confidence to untested mono-alkylphenols in 21 
the category. These simple alkylphenols are non-reactive and exhibit an unspecific, reversible 22 
polar narcosis mode of toxic action. Briefly, polar narcotics act via unspecific, reversible 23 
interactions with biological membranes in a manner similar to cataleptic anaesthetics. The read-24 
across premise includes rapid and complete absorption via the gastrointestinal tract, distribution 25 
in the circulatory system, first-pass Phase 2 metabolism in the liver, and elimination of sulphates 26 
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and glucuronides in the urine. Thus, toxicokinetic parameters are considered to be similar and 27 
have the same toxicological significance. Five analogues have high quality experimental oral 28 
repeated-dose toxicity data (i.e., OECD TG 408 or OECD TG 422). These repeated-dose toxicity 29 
test results exhibit qualitative consistency in symptoms. Typical findings include decreased body 30 
weight and slightly increased liver and kidney weights which are generally without concurrent 31 
histopathological effects. The sub-chronic findings are quantitatively consistent with the No 32 
Observed Adverse Effect Level (NOAEL) of ≥ 50 mg/kg bw/d. 33 
Chemical similarity between the analogues is readily defined, and data uncertainty associated 34 
with the similarities in toxicokinetic properties, as well as toxicodynamic properties, are low. 35 
Uncertainty associated with mechanistic relevance and completeness of the read-across is low-36 
to-moderate, largely because there is no adverse outcome pathway or intermediate event data. 37 
Uncertainty associated with mechanistic relevance and completeness of the read-across is 38 
reduced by the concordance of in vivo, in vitro, USEPA toxicity forecaster (ToxCast) results, as 39 
well as the in silico data. The rat oral repeated-dose NOAEL values for the source substances can 40 
be read across to fill the data gaps of the untested analogues in this category with uncertainty 41 
deemed equivalent to results from a TG 408 assessment. 42 
. 43 
Keywords: read-across, mono-alkylphenols, repeated-dose toxicity, No Observed Adverse 44 
Effect Level (NOAEL), Lowest Observed Adverse Effect Level (LOAEL), weight-of-evidence 45 
(WoE), uncertainty 46 
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Highlights: 48 
 24 short-chain (C4 or less) mono-alkylphenols were selected for read-across 49 
 Alkylphenols exhibit an unspecific, reversible polar narcosis mode of action  50 
 Six analogues with high quality repeated-dose toxicity data serve as source chemicals  51 
 Uncertainty is reduced by the concordance of in vivo, in vitro, ToxCast and in silico data  52 
 A NOAEL of 50 mg/kg bw/d may be read across to fill data gaps for untested analogues 53 
  54 
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1 Introduction 55 
1.1 Read-across 56 
Grouping of organic chemicals with the intention of conducting read-across is a method that has 57 
application in regulatory toxicology. The principal philosophy of a toxicological read-across is 58 
that chemicals that are similar in molecular structure exhibit similar chemical properties and in-59 
so-doing, demonstrate similar toxicokinetic and toxicodynamic properties. As a consequence, 60 
experimentally-derived toxicokinetic and toxicodynamic properties from one or several 61 
substance(s), the source chemical(s), can be read across to fill the data gap for other substances, 62 
the target chemicals. This type of data gap filling is particularly useful for cosmetic ingredients, 63 
where in vivo testing in Europe is legislatively prohibitive [1]. 64 
Read-across arguments can be used for different purposes. The style of the read-across often 65 
differs with purpose. A wide-domain style is typically associated with screening and priority 66 
setting. Wide-domain applications have multiple target chemicals, often one, but generally three 67 
or less source substances. In contrast, narrow-domain read-across exercises include ones 68 
associated with the development of a substance-specific assessment, such as with a REACH 69 
dossier. In this case study, the wide-domain approach is used. 70 
1.2 Short-chain alkylphenols: an overview of existing knowledge  71 
Alkyl-substituted phenols are a structurally complex group of compounds, which differ in both 72 
the substituent size and shape and positions of substitution on the phenolic ring. They are 73 
hypothesised to act as polar narcotics by way of unspecific, reversible interactions with 74 
biological membranes in a manner similar to cataleptic anaesthetics. There are sufficient in vivo 75 
data available and there are also in vitro data from ToxCast for several of the chemicals in this 76 
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class [2]. In a preliminary investigation of alkylphenols, it was revealed that in vivo oral 77 
repeated-dose exposure to alkyl-substituted phenols gives rise to a variety of toxicity symptoms 78 
including toxicities involving the liver, kidney, blood and whole body effects with No Observed 79 
Adverse Effect Level (NOAEL) values ranging from >100 to <10 mg/kg bw/d [3]. Moreover, 80 
experimental results of toxicokinetics parameters are inconsistent. These toxicokinetic and 81 
toxicodynamic differences increase uncertainty associated with read-across [4]. Endpoint 82 
specific factors affecting prediction uncertainties include how molecular structure impacts 83 
metabolism and clearance, as well as repeated-dose potency. 84 
1.3 Goal and aims 85 
From our preliminary investigation, we conclude that alkylphenols are not likely to form a single 86 
category for repeated-dose toxicity read-across. Further, we hypothesised based on 87 
bioavailability, and distribution, and mechanistic considerations, it was highly likely that a single 88 
category could be formed for mono-alkylphenols, especially short-chain (i.e., C4 or less) 89 
derivatives. It is the intent of this case study to demonstrate that short-chain, mono-alkylphenols 90 
provide a high-quality example whereby the category approach to read-across may provide 91 
predictions for filling data gaps for the oral gavage sub-chronic repeated-dose endpoint. In this 92 
scenario, the chemical category represents analogues which are non-reactive and exhibit no 93 
specific mode of toxic action, and metabolism being consistent across the domain has minimal 94 
toxicological relevance. 95 
The particular aims in this read-across case study were: 1) the use of online ECHA registrations 96 
information as a primary guide to and source of toxicokinetic and toxicodynamic data, 2) the 97 
incorporation of sub-chronic repeated dose toxicity data and data for alkylphenols residing 98 
outside the applicability domain of the case study, and 3) the incorporation of high-through-put 99 
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screening (HTS) data in the form of ToxCast data [5,6] and of in silico nuclear receptor binding 100 
predictions [7]. The specific aim of using all sub-chronic repeated-dose toxicity data (e.g., data 101 
from Organization for Economic Co-Operation and Development (OECD) test guidelines (TG) 102 
408, TG 422 and TG 407 studies) was to increase the in vivo weight-of-evidence (WoE) and 103 
thereby reduce toxicokinetic and toxicodynamic uncertainties. The specific aim of the HTS data 104 
and in silico predictions was to reduce uncertainty associated with mechanism plausibility. 105 
As a case study, this category assessment is designed to illustrate specific issues associated with 106 
predicting sub-chronic health effects [8]. It is not intended to be related to any regulatory 107 
discussions on this chemical group. 108 
2 Preliminary Investigations 109 
2.1. Toxicokinetic differences 110 
A preliminary examination of data revealed that the alkyl substitution pattern of phenol impacts 111 
toxicokinetics. In particular, the size and number of the ortho-substitution impact metabolism, as 112 
does substitution in the para-positions. While species differences in metabolism of phenol have 113 
been shown, humans and rats showed similar metabolic pathways and quantities of metabolites 114 
in urine [9]. It was concluded that the rat is likely a good surrogate for human metabolism of 115 
phenol. 116 
Hughes and Hall investigated the metabolism and clearance of phenol in rats [10]. The study was 117 
comparable to OECD TG 417 with acceptable restrictions. Briefly, female F344 rats (3-4/ group) 118 
received 0.03 mg/kg bw 14C-labelled phenol via oral administration. Radioactivity in urine and 119 
faeces was analysed after sampling in metabolism cages; the animals were sacrificed 72 h after 120 
application and radioactivity in organs, carcass and washings determined. 121 
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Phenol showed rapid and complete absorption and was distributed throughout the body after oral 122 
exposure. Of the administered radioactivity, 70-85% of the recovered dose was excreted in urine 123 
4 hours after administration and urinary elimination was essentially complete by 12 hours. After 124 
72 hours, 95% of the applied dose was excreted via urine and only 1-3% was excreted via faeces. 125 
Specifically, after oral dosing 63.4 ± 2.3% was excreted as phenyl sulphate and 26.8 ± 2.7% was 126 
excreted as phenyl glucuronides. Similar findings are reported for methylphenols [11]. 127 
Takahashi and Hiraga conducted an investigation of the metabolism and clearance of 2,4,6-128 
tritertbutylphenol in rats [12]. Clearance studies (dosed by oral gavage and in the diet) and the 129 
analysis of urinary and faecal metabolites (dosed via the diet) took place.  130 
For clearance studies, male Sprague-Dawley rats received oral doses (260 mg/kg) of 2,4,6-131 
tritertbutylphenol by gavage in soy bean oil following overnight starvation; rats given 2,4,6-132 
tritertbutylphenol via the diet ad libitum were also used for clearance studies. At various times, 133 
rats were killed and blood, liver, spleen, kidneys, testes and samples of epididymal adipose tissue 134 
were collected for analysis. For the analysis of biliary excreted metabolites, the bile duct was 135 
cannulated with polyethylene tubing for the collection of bile. For the analysis of urinary and 136 
faecal metabolites, rats were fed a diet containing 0.2 % test material for two days, and urine and 137 
faeces were collected.  138 
Single oral doses were well-absorbed in the rat. Peak blood levels of the test material were 139 
reached in 15 to 60 minutes. The blood elimination half-lives were 18.2 minutes for the α-phase 140 
and 11.8 hours for the slower β-phase. Maximum tissue concentrations were reached after 2 to 3 141 
hours in the liver, 2 to 6 hours in the kidneys, 1.5 to 2.5 hours in the spleen and >24 hours in 142 
epididymal adipose tissues. 143 
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2,4,6-Tritertbutylphenol and its metabolites were not excreted in the urine; a metabolite but not 144 
the parent compound was detected in the faeces. The faecal metabolite had a molecular weight of 145 
261 gm/mol and was considered to be a 2,4,6-tritertbutylphenoxy radical. The phenoxy radical 146 
was also detected in the bile of rats.  147 
Several metabolic pathways and numerous metabolites of 2,6-ditertbutyl-4-methylphenol are 148 
known. The main metabolic pathway leads to the alcohol, aldehyde and acid derivatives by 149 
stepwise oxidation of the 4 -methyl group [13]. However, a cyclic metabolic pathway via quinoid 150 
metabolites (i.e., 2,6-ditertbutyl-4-hydroperoxy-4-methyl-2,5-cyclohexadienone and 151 
2,6ditertbuty-4-hydroxy-4-methyl-2,5-cyclohexadienone) has been described in rat liver 152 
microsomes [14]. Yamamoto et al. detected reactive metabolites (i.e., 2,6-ditertbutyl-p-153 
benzoquinone and 2,6-ditertbutylhydroquinone) possibly also a result from this pathway [15]. A 154 
further quinoid metabolite, 2,6-ditertbutyl-4-methylene-2,5-cyclohexadienone is considered to be 155 
a possible reactive metabolite [16]. 156 
Conning and Phillips studied the toxicokinetics of 2,6-ditertbutyl-4-methylphenol following oral 157 
administration [17]. For most species, hindered phenols (ortho-substituted) are cleared slower 158 
than unhindered phenols, due to increased enterohepatic circulation. Oxidative metabolism (i.e., 159 
phase 1 reactions) is mediated by the microsomal monooxygenase system; oxidation of the ring 160 
methyl group predominates in the rat, rabbit and monkey, while oxidation of the tertbutyl groups 161 
predominates in humans. Gallates and 2-tert-butylhydroquinone are the main metabolic products 162 
of non-oxidative pathways with methylation or conjugation with sulphate and glucuronic acid.  163 
Doergea et al. studied the metabolism and disposition of isomers of 4-nonylphenol orally 164 
administrated by gavage at 0, 0, 1.25, 10 and 50 mg/kg/bw/d and by feed 50 mg/kg to Sprague-165 
Dawley male and female rats [18]. The results showed that 4-nonylphenol was rapidly absorbed 166 
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in serum – average half-time is 0.8 hour. The aglycone content was measured in livers from rats 167 
on the 50 mg/kg diet. Tissue accumulation of 4-nonylphenol aglycone was observed despite the 168 
predominance of glucuronidation in blood. The largest difference between females and males 169 
was observed in the livers with more similar levels observed in kidney and brain. Reproductive 170 
tissues generally contained low levels of total 4-nonylphenol with the exception of prostate.  171 
Rapid first-pass metabolism was observed and two major glucuronides were observed in rat 172 
serum and liver by LC-ES/MS analysis. Substantial amounts of p-nonylphenol-catechol 173 
glucuronides were also observed in serum and liver. The major routes of excretion of 4-174 
nonylphenol are via the faeces.  175 
In summary, while phenol and methylphenols are rapidly eliminated in the urine as phase 2 176 
conjugates, 2,4,6-tritertbutylphenol and 2,6-ditertbutyl-4-methylphenol are cleared from the body 177 
more slowly. 4-Nonylphenol is also eliminated rapidly, however, the main route is via the feaces. 178 
Moreover, while phenol and methylphenols follow a single metabolic pathway, 2,4,6-179 
tritertbutylphenol,2,6-ditertbutyl-4-methylphenol and 4-nonylphenol follows several metabolic 180 
pathways with numerous reactive metabolites being identified. 181 
2.2 Toxicodynamic differences 182 
A European Commission study reports data on sub-chronic oral toxicity of phenol in rats [19]. 183 
This study is considered comparable with an OECD TG 408 bioassay with restrictions (i.e., 184 
histopathology only for spleen, thymus, liver, kidneys, and male reproductive organs). Phenol 185 
was investigated for repeat-dose toxicity in male Sprague-Dawley rats exposed for 13 weeks via 186 
the drinking water at concentrations of 0, 200, 1000, 5000 mg/l (calculated to be 0, 15, 71, and 187 
300 mg/kg bw/d). At the high dose level, decreased body weight/body weight gain, decreased 188 
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water and food consumption, and increased organ to body weight ratios were detected. It was 189 
concluded that reported effects were secondary to water avoidance due to flavour aversion. The 190 
NOAEL of phenol in drinking water was reported to be 1000 mg/l (71 mg/kg bw/d). 191 
Sub-chronic oral toxicity studies of methylphenols (gavage dosing at 0, 50, 150, 450 mg/kg 192 
bw/d) have been reported [3]. At high doses (150 or 450 mg/kg bw/d) rats displayed lethargy, 193 
tremors, hunched posture and rough fur. There was a dose-dependent decrease in body weight or 194 
reduction in body weight increases. The NOAEL values are between 50 and 150 mg/kg bw/d. 195 
Matsumoto et al. reports chronic oral toxicity results for 2,4,6-tritertbutylphenol from an OECD 196 
TG 452 study [20]. Briefly, 40 male and female per dose Slc:Wistar rats were exposed via the 197 
diet to 0, 30, 100, 300 and 1000 ppm for 24 months, with interim examinations at 6, 12 and 18 198 
months. The highest dose (1000 ppm) was equivalent to approximately 1/20 of the LD50 value 199 
(1670 mg/kg in males of the same strain) obtained from a preliminary acute toxicity study. The 200 
general condition of the animals was observed and body weights were recorded throughout the 201 
study. At 6, 12, 18 and 24 months after feeding on treated diet, haematological and serum 202 
biochemical examinations were conducted for all dose groups. Also, following 6, 12, 18 and 24 203 
months of exposure, histopathological examinations were performed for all groups. 204 
Mortality in treated rats was comparable to that of controls (provide control mortality level or 205 
indicate no mortality). No remarkable general findings in food consumption were observed in the 206 
control and treated groups throughout the experimental period. Substantial reduction of body 207 
weight gain was found in the female 1000 ppm group from 12 months onward. No significant 208 
changes in food consumption were observed in the control and treated groups throughout the 209 
experimental period. The haematological, biochemical and histopathological examinations 210 
revealed slight microcytic anaemia, changes in some biochemical parameters relating to liver 211 
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function (e.g. phospholipids, total cholesterol, glutamate oxaloacetate transaminase and γ-212 
glutamyl transpeptidase) and focal necrosis of liver cells following test material administration.  213 
The changes observed in females were more severe than those in males. No neoplastic response 214 
following test material administration was noted. In summary, the study concluded that 2,4,6-215 
tritertbutylphenol causes liver injury characterised by focal necrosis with microcytic anaemia and 216 
elevations of serum phospholipids and cholesterol levels, presumably occurring as secondary 217 
effects following the liver injury. Under the conditions of this study, the LOAEL was determined 218 
to be 100 ppm (167 mg/kg bw/d); the NOAEL was determined to be 30 ppm (50.1 mg/kg bw/d). 219 
From our preliminary investigation of available studies, we conclude that alkylphenols are not 220 
likely to form a single category for repeated-dose toxicity read-across. However, we do 221 
hypothesize it is likely that a single category could be formed for mono-alkylphenols, especially 222 
short-chain (i.e., C4 or less) derivatives. The multi-substituted alkylphenols and alkylphenols 223 
with longer (C5 or more) alkyl groups do not belong to this category because of differences in 224 
toxicokinetics. 225 
3. Method and Materials 226 
This evaluation of selected alkylphenols is generally consistent with the read-across workflow of 227 
Schultz et al (2015) [8]. This evaluation is also consistent with the guidance proposed by the 228 
OECD [21]. In vivo toxicokinetic and toxicodynamic data used in the assessment were taken 229 
from the literature and the European Chemicals Agency (ECHA) REACH Registered Substances 230 
database [22]. Mechanistic relevance, as well as toxicological similarity of the category 231 
members, was further established using relevant non-animal data. 232 
3.1 Target and source substances 233 
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The short-chain mono-alkylphenols evaluated in this study are listed in Table 1. They include 19 234 
potential target substances and six source chemicals (noted in bold). This list is not meant to be 235 
all inclusive. Rather, it represents existing industrial organic materials that are likely to be found 236 
in a governmental or industrial inventory (e.g., OECD High Production Volume Chemicals). 237 
Short-chain was defined as having alkyl-substituents of C4 or less. 238 
Table 1. Short-chain, mono-substituted, alkyl phenols evaluated in the case study. 239 
ID Name CAS number 
1 2-methylphenol 95-48-7 
2 3-methylphenol 108-39-4 
3 4-methylphenol 106-44-5 
4 2-ethylphenol 90-00-6 
5 3-ethylphenol 620-17-7 
6 4-ethylphenol 123-07-9 
7 2-propylphenol 644-35-9 
8 3-propylphenol 621-27-2 
9 4-propylphenol 645-56-7 
10 2-isopropylphenol 88-69-7 
11 3-isopropylphenol 618-45-1 
12 4-isopropylphenol 99-89-8 
13 2-butylphenol 3180-09-4 
14 3-butylphenol 28805-86-9 
15 4-butylphenol 1638-22-8 
16 2-isobutylphenol 4167-75-3 
17 3-isobutylphenol 30749-25-8 
18 4-isobutylphenol 4167-74-2 
19 2-secbutylphenol 89-72-5 
20 3-secbutylphenol 3522-86-9 
21 4-secbutyphenol 99-71-8 
22 2-tertbutylphenol 88-18-6 
23 3-tertbutylphenol 585-34-2 
24 4-tertbutylphenol 98-54-4 
 240 
3.2 Endpoint 241 
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The NOAEL for sub-chronic rat oral repeated-dose is the endpoint for which this category-242 
approach to read-across is applied. The 90-day oral gavage repeated-dose data for 2-243 
methylphenol, 3-methylphenol, and 4-methylphenol are well suited for reading across. These 244 
three analogues have been examined for toxicokinetics and the experimental NOAELs are based 245 
on experimental results from multi-dose gavage exposure scenario and following test guidelines 246 
similar to OECD TG 408 where the LOAEL symptoms are reported. The data are highly similar 247 
both qualitatively and quantitatively. Additionally, three other analogues with longer side chains 248 
(2-secbutylphenol, 2-tertbutylphenol and 4-tertbutylphenol) have the experimental NOAEL 249 
values obtained via studies following test guidance similar to OECD TG 407 and TG 422. Only 250 
one of them - 4-tertbutylphenol - was examined for toxicokinetics.  251 
3.3 Hypothesis of the category 252 
The initial hypothesis for this read-across case study is: 253 
 Short-chain (i.e., C4 or less), mono-substituted alkyl phenols are chemically similar with 254 
structure and property differences that are not relevant to repeated-dose potency. 255 
 Short-chain, mono- substituted alkyl phenols are readily absorbed from oral 256 
administration, readily distributed via the blood, similarly metabolised in the liver and 257 
readily excreted via the urine. 258 
 Short-chain, mono- substituted alkyl phenols elicit similar qualitative and quantitative 259 
repeated-dose toxicity. In vivo, they exhibit no systemic toxicity. In vitro and in silico, 260 
they exhibit no chemical reactivity; nor do they exhibit any receptor-mediated 261 
interactions which are endpoint-relevant. 262 
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4 Results 263 
4.1 Applicability domain 264 
After elimination of multi-substituted alkylphenols and alkylphenols with large alkyl group (e.g., 265 
4-nonylphenol) due to toxicokinetic considerations, the applicability domain was limited to 266 
mono-alkyl substituted phenols with carbon chain lengths from C1 to C4. Specifically, these 267 
derivatives included ones substituted in the 2-, 3-, or 4-position (Table 1). While data for phenol, 268 
mixtures of mono-ethylphenols, di-methylphenols and 2-isopropyl-5-methylphenol are reported 269 
and used in support of the read-across, mixtures are not included in category at this time. 270 
4.2 Purity/impurities 271 
A purity/impurity profile for the analogue listed in Table 1 is not reported. No effort was made to 272 
take into account impurities based on production. Since the category is structurally limited, the 273 
impurities are expected to be similar if not the same across the members and are not expected to 274 
significantly impact the toxicity profile of any analogue. However, it is acknowledged for 275 
regulatory decisions such information may be required. 276 
4.3 Read across justification 277 
In order to conduct a read-across, there is the requirement of high quality in vivo data for the 278 
endpoint under consideration, which in this case is sub-chronic oral gavage repeated dose-279 
toxicity for rat in the form of a NOAEL value. 280 
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Table 2. Summary of repeated-dose and toxicokinetic information for selected alkylphenols. 281 
Chemical Name 
Route of 
administrati
on 
TG408 
LOAEL 
(mg/kg bw/d) 
TG408 
NOAEL 
(mg/kg bw/d) 
TG422 
LOAEL 
(mg/kg bw/d) 
TG422 
NOAEL 
(mg/kg bw/d) 
TG407 
LOAEL 
(mg/kg bw/d) 
TG407 
NOAEL 
(mg/kg bw/d) 
Toxicokinetic 
Study 
2-methylphenol Gavage 175 50         
Bray et al. 
[23] 
2-methylphenol Diet 325 ≈25         
Bray et al. 
[23] 
3-methylphenol Gavage 150♂   50♂ 1000♂ 300♂     
Bray et al. 
[23] 
3-methylphenol Gavage 450♀ 150♀ 300♀ 100♀     
Bray et al. 
[23] 
4-methylphenol Gavage 175 50         no 
2-secbutylphenol Gavage   60 12     no 
4-tertbutylphenol Gavage     200♂ 60♂     
Koster et al. 
[24] 
2-tertbutylphenol Gavage         500 100 no 
mixture of 3- & 
4-methylphenol  
Diet (TG 416) ≈70 NA         
Morinaga et 
al. [11]  
mixture of 2-, 3- 
& 4-ethylphenol  
Gavage     245 100     no 
mixture of 
dimethylphenols  
Gavage     245 100     no 
Phenol 
Drinking 
water 
(TG451) 
        300 71 
Hughes and 
Hall [10] 
2-isopropyl-5-
methylphenol 
Gavage     40 8     
Austgulen et 
al. [25] 
Information sourced from [22] 282 
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The sub-chronic oral repeated-dose data were collected for six alkylphenols with different length 
of side chain (methyl, sec-butyl and tert-butyl). Having diverse (in terms of side chain size) 
source chemicals adds strength to read-across justification as well as allowing for an interpolation 
rather than an extrapolation of data. Although there are differences in the protocols of the sub-
chronic studies, the results exhibit qualitative and quantitative consistency. . Additionally, to 
eliminate the uncertainty that reduced food or drinking water consumption was due to flavour 
aversion caused by the phenols, only data from gavage studies were read across.  
4.4 Similarities in chemistry 
Chemical structure and property values are reported in Tables 1 – 3 of the supplementary material. 
4.4.1 Structural similarity 
All the alkyl phenols included in Table 1 belong to a common chemical class, phenols, and the 
subclasses alkyl phenols and mono-substituted phenols, and they possess a benzene backbone as 
common molecular scaffolding. The main structural variables in the groups are the shape and size 
of the alkyl-substituents and the positions of the substituents in relationship to the hydroxyl group 
(see supplementary material Table 3). 
4.4.2 Chemical property similarity 
The experimental physico-chemical properties for alkyl phenols included in Table 1 are presented 
in supplementary material (Table 2). Properties, with the exception of density, tread in values 
related to C-atom number within a scaffold. Specifically, all category members exhibit molecular 
weights from 100 to 150g/mol. While hydrophobicity (log Kow) increases with number of C-
atoms from 2.00 to 3.30, density is constant at 1.0 g/cm3. While vapour pressure and water 
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solubility decrease with molecular size, melting point and boiling point increase with molecular 
size. 
In summary, the differences in chemistry observed between the analogues within the category are 
hypothesized to minimal and not considered to be toxicologically significant and not preclude read 
across for the relevant to the repeated-dose endpoint. 
4.5 Similarities in toxicokinetics 
Key toxicokinetic studies are listed in Table 2 and are reported in details in Sections 4.5.1 and 
4.5.2. Based on the results of five toxicokinetic studies, the absorption, distribution, metabolism 
and elimination (ADME) properties for the short-chain, mono-substituted, alkylphenols in Table 1 
are similar. All the phenols in the proposed category are predicted to be readily absorbed from the 
gastrointestinal tract and distributed in the blood. First pass metabolism is most likely to be phase 
II conjugation to glucuronides and sulphates. Elimination is predicted to be rapid (half-life of 
hours) and mainly via the urine. The relative amounts of specific metabolites are likely to differ 
between analogues (greater conjugation with higher C-number and degree of branching) and also 
vary with dose (greater amount of conjugation with dose assuming higher doses do not saturate). 
4.5.1 Similarities in toxicokinetics of mono-alkylphenols 
Morinaga et al. reported on the toxicokinetics of an oral-administered cresol soap solution 
containing 3-methyl- and 4-methylphenol [11]. In Wister rats, the phenols were readily absorbed, 
distributed throughout the body, eliminated, for the most part, within several hours and excreted 
mainly as glucuronide and sulphate metabolites. 
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Bray et al. reported the results of a single oral application of 2-methylphenol by gavage to rabbits 
[23]. 2-Methylphenol dissolved in bicarbonate was administered and urinary excretion was 
collected over 24 hours. Results showed that 80% of the dose was excreted in the urine, 55-91 % 
as glucuronides, 13-19 % as sulphates and 0-2 % as free 2-methylphenol. 
Bray et al. reported the results of a single oral application of 3-methylphenol by gavage to rabbits 
[23]. Three-methylphenol dissolved in bicarbonate was administered and urinary excretion was 
collected over 24 hours. Results showed that the 3-methyl derivative was excreted mainly in the 
urine: 53-70 % (of the administered dose) as glucuronides, 4-15 % as sulphates and 0-4 % as free 
3-methylphenol. 
Koster et al. examined the toxicokinetics of 4-tertbutylphenol in rats. Absorption following oral 
administration in rats is rapid and complete [24]. Elimination of an oral dose (147 µg/kg bw/d for 
3 days) was via urine and faeces, 72.9% and 26.7%, respectively. The retention of 4-
tertbutylphenol in rats has been shown to be only 0.1% 7 days after an oral dosing. While urinary 
metabolites were sulphate and glucuronide conjugates, whether the material detected in faecal 
samples occurred as unabsorbed 4-tertbutylphenol or as its metabolites eliminated via bile was not 
determined. Following oral absorption, a small amount of 4-tertbutylphenol is distributed to the 
liver in rats but not to adipose tissue or lungs. 
In summary, following oral exposure short-chain, mono-alkylphenols are readily bioavailable. 
Since the pKa of phenol and alkylphenols is between 9 and 10.6, at physiological pH, these 
phenols are essentially 100% non-ionized. Uncharged phenols, as compared to ionized phenols, 
are assumed to more readily partition across cell membranes and be absorbed in gastrointestinal 
tract. Metabolism is typically via phase II conjugation to glucuronides and sulphates. Elimination 
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is rapid (half-life of hours) and takes place mainly via the urine. The relative amounts of specific 
metabolites differ between analogues and also vary with the dose. 
4.5.2 Supporting toxicokinetic data 
The above findings are supported by the study of Austgulen et al. [25], who reported toxicokinetic 
data for 6 male Wistar rats exposed by gavage to a single application (1 mmol; 150.22 mg/kg bw) 
of 2-isopropyl-5-methylphenol dissolved in propylene glycol. Briefly, urine samples were 
collected and stored at -10°C in 24 hour intervals and analysed by chromatography after conjugate 
hydrolysis. The urinary excretion of metabolites was rapid, with only very small amounts excreted 
after 24 hours. The administered 2-isopropyl-5-methylphenol was excreted unchanged (or as 
glucuronide and sulphate conjugates). Additionally the following non-reactive metabolites were 
identified: 2,5-dihydroxy-p-cymene, 2-(2-hydroxy-4-methylphenyl)propan-1-ol, 5-
hydroxymethyl)-2-(1-methylethyl)phenol, 2-(4-hydroxymethyl-2-hydroxyphenyl)propan-1-ol, 2-
(2-Hydroxy-4-methylphenyl) propionic acid, 3-Hydroxy-4-(1-methylethyl) benzoic acid.    
4.6 Similarities in toxicodynamics 
4.6.1 Similarities in repeated-dose toxicity: OECD TG 408 
Experimental 90-day oral gavage repeated-dose toxicity data for 2-methylphenol, 3-methylphenol 
and 4-methylphenol was generated by Dietz et al. [26] based on the protocol of Sontag, Page and 
Saffotti (NCI, DHEW Publication No. (NIH)78-ß01 Guidelines for Carcinogen Bioassay), which 
is similar to OECD TG 408.  
Briefly, in this study 2-methylphenol diluted in corn oil was administered daily to Sprague-Dawley 
rats (30/sex/dose) by gavage at dose levels of 0, 50, 175, 600 mg/kg bw/d for up to 13 weeks. At 
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600 mg/kg bw/d significant mortality (i.e., 19/30 ♀ and 9/30 ♂) was observed. While body 
weights of females were unaffected, the body weight gain in males at 175 and 600 mg/kg bw/d 
was reduced. There was a slight decrease in food intake in the 600 mg/kg bw/d group in both 
sexes. Treatment-related depression of the central nervous system (i.e., lethargy, dyspnoe, tremor 
and/or convulsions) was observed, with recovery within 1 h after dosing. No effects on clinical 
chemistry, haematology, organ weights or treatment-related gross and histopathology were 
reported. Regardless of sex, the 90-day LOAEL was 175 mg/kg bw/d, while the NOAEL was 50 
mg/kg bw/d. 
3-Methylphenol diluted in corn oil was administered daily to Sprague-Dawley rats (30/sex/dose) 
by gavage at dose levels of 0, 50, 150, 450 mg/kg bw/d for 13 weeks. At 450 mg/kg bw male and 
female rats displayed lethargy, tremors, hunched posture and rough fur post-dosing. Dose-
dependent body weight decrease in males at 150 mg/ kg bw/d resulted in a male NOAEL of 50 
mg/kg bw/d; based on reduced body weight gain in females at 450 mg/ kg bw/d, the 90-day female 
NOAEL was 150 mg/kg bw/d [26]. 
4-Methylphenol diluted in corn oil was administered daily to Sprague-Dawley rats (30/sex/dose) 
by gavage at dose levels of 0, 50, 175, 600 mg/kg bw/d for 13 weeks. Based on increased 
mortality, clinical signs (i.e., lethargy, excessive salivation, tremor and occasional convulsions and 
comas), as well as hepatotoxicity and nephrotoxicity in both sexes, the LOAEL was reported as 
175 mg/kg bw/d. The 90-day NOAEL was reported as 50 mg/kg bw/d for both sexes [26]. 
A reliable without restrictions study reports the 90-day feeding oral toxicity of 2-methylphenol 
[27]. Following OECD TG 408, Fischer 344 rats (20/sex/dose) were fed diets containing 0, 1880, 
3750, 7500, 15000, 30000 ppm ( 160, 325, 650, 1300 and 2600 mg/kg bw/d) 2-methylphenol for 
13 weeks. While no mortality was observed, decreased body weight gain was recorded at the 
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highest dose. No clinical signs of toxicity were reported. Increased relative kidney and liver 
weights were observed at the three highest doses; however, haematology and clinical chemistry 
findings were “unremarkable”. Similarly, histopathology findings were minimal and considered 
likely secondary to the decreased weight gains. 
In summary, at higher doses (<450 mg/kgbw/d), 90-day repeated oral gavage exposure to 
methylphenols result in displays of lethargy, tremors, and hunched posture. Dose-dependent body 
weight decrease is observed at intermediate doses. Histopathology findings, when noted, were 
minimal and considered likely secondary to the decreased weight gains. Increased relative kidney 
and liver weights, when noted, are likely compensatory to metabolism. Typically, experimental 
NOAEL values of 50 mg/kg bw/d are reported. 
4.6.2 Similarities in repeated-dose toxicity: OECD TG 422, and TG 407 
A reliable with restrictions study reports findings for 2-secbutylphenol from a study design similar 
to OECD TG 422. Crj:CD(SD) rats (13/sex/dose group) were dosed by oral gavage to 0, 12, 60 
and 300 mg/kg bw/d (corn oil carrier) [28]. Males were exposed for 42 days, females, from 14 
days before mating up to day three of lactation. No animals died in any groups. In the 300 mg/kg 
bw/d group the following symptoms were observed: 1) salivation after dosing, decrease in activity 
and incomplete eyelid opening in males and females, 2) an ataxic gait was in females, 3) an 
increase in relative liver weight with males and females, and hypertrophy of the centrilobular 
hepatocytes in males, 4) concentration of total cholesterol was increased in males, and 5) no 
adverse effects were detected on food consumption and body weight change in males and females. 
In the 60 mg/kg group, decrease in locomotor activity was observed in a few males early in the 
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administration period. The “NOELs” for repeat dose toxicity of 2-secbutylphenol are considered to 
be 12 mg/kg/d in males and 60 mg/kg/d in females. 
The US EPA [3] reported repeated-dose toxicity data for 4-tertbutylphenol. In a 14-day range-
finding study (for the definitive study below), Sprague-Dawley rats (5/sex/dose) were 
administered 4-tertbutylphenol daily via gavage in 0.5% aqueous methyl cellulose at 0, 250, 500 
and 1000 mg/kg bw/d. At 1000 mg/kg bw/d, mortality (3 of 5 females and 1 of 5 males) and 
decreased body weight were observed. Two females at this dose had difficulty breathing. No signs 
of toxicity were noted when the animals were necropsied. A dose of 250 mg/kg bw/d was 
considered an appropriate dose level for this study [3]. 
In a combined repeated-dose/reproductive/developmental toxicity screening test following OECD 
TG 422, male and female Sprague-Dawley rats (13 sex/dose) were administered 4-tertbutylphenol 
via gavage in 0.5% aqueous methyl cellulose at 0, 20, 60 and 200 mg/kg bw/d [29]. Males were 
exposed for 44 days; females were exposed from 14 days before mating to day 4 of lactation. At 
the highest dose tested, some females showed stridor associated with dyspnea, likely caused by 
irritation of the respiratory tract as a result of the gavage dosing. In the same test group, males 
exhibited decreased plasma albumin. In parental animals, no compound specific morphological 
changes were observed. Examination of body weights and gross morphology of the offspring 
revealed no effects of the compound administration and no other treatment-related changes were 
observed. A NOAEL of 60 mg/kg bw/d was reported for 4-tertbutylphenol. 
A study following OECD TG 422 reported the sub-chronic oral toxicity of a mixture of 2-, 3-, and 
4-ethylphenol (29%, 32% and 39%, respectively) [30]. Crl:CD (SD)IGS BR VAF/Plus rats (10/ 
sex/dose) were exposed by gavage in corn oil to 0, 30, 100 and 245 mg/kg bw/d. Males were 
exposed for 28 days and females were exposed 54 days. Observations of viability, clinical signs of 
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toxicity, food consumption, body weight gain, functional observational battery and motor activity, 
haematology, clinical chemistry, as well as gross and microscopic post-mortem examination were 
undertaken. All rats survived the treatment. In males, urine-stained fur was observed at the 245 
mg/kg/day level. Body weight gain and food consumption were unaffected by treatment. 
Symptoms associated with neurotoxicity were not observed during the study, and there were no 
treatment related effects observed at gross necropsy or with histopathology. Due to urine-stained 
fur, increased kidney, liver and ovarian relative weights at 245 mg/kg bw/d, the NOAEL was 
reported as 100 mg/kg bw/d. 
Another study following OECD TG 422 reported the sub-chronic oral toxicity of a mixture of 
dimethyl-substituted phenols [31]. The tested material included: 2,5-xylenol (95-87-4): 16.4 mole 
%, 3,4-xylenol (95-65-8): 16.9 mole %, 2,4-xylenol (105-67-9): 22.7 mole %, 3,5-xylenol (108-
68-9): 11.1 mole %, 2,3-xylenol (526-75-0): 18.2 mole %, and 2,6-xylenol (576-26-1): 14.7 mole 
%. Crl:CD (SD)IGS BR VAF/Plus rats (10/ sex/dose) were exposed by gavage in corn oil to 0, 30, 
100 and 245 mg/kg bw/d. Males were exposed for 28 days and females were exposed for 54 days. 
Viability, clinical signs of toxicity, food consumption, body weight gain, functional observational 
battery and motor activity, haematology, clinical chemistry, as well as gross and microscopic post-
mortem examination were assessed. All rats survived the treatment. In males, urine-stained fur was 
observed at the 245 mg/kg/day level. Body weight gain and food consumption were unaffected by 
treatment. Symptoms associated with neurotoxicity were not observed during the study, and there 
were no treatment related effects observed at gross necropsy or with histopathology. Due to urine-
stained fur, increased kidney, liver and ovarian relative weight at 245 mg/kg bw/d, the NOAEL 
was reported as 100 mg/kg bw/d. 
25 
 
In a reliable with restrictions study, 2-tertbutylphenol was assessed following a procedure similar 
to OECD TG 407 [32]. In this 28-day repeated-dose study, Crj:CD(SD)IGS rats (6/sex/dose) were 
administered 2-tertbutylphenol in olive oil by gavage at doses of 0, 4, 20, 100 and 500 mg/kg 
bw/d. No treatment-related changes in body weight, food consumption, haematology, blood and 
urine chemistry, urinalysis were noted. Necropsy and histopathological examination were 
unremarkable. Clinical signs of ataxic gait were observed in both males and females in the 500 
mg/kg group. Transient salivation within 30 minutes of dosing was observed as the only clinical 
sign in males and females in the 100 mg/kg group. For both sexes, the NOAEL values for 2-
tertbutylphenol were reported as 100 mg/kg bw/d.  
Consistent with the above studies, a reliable with restrictions study reported the results of an 
OECD TG 451 assay using F344/N male rats that were fed a mixture containing 60 % 3-
methylphenol and 40 % 4-methylphenol [33]. In this carcinogenesis study, groups of 50 rats were 
fed diets containing the mixture at 0, 1,500, 5,000 or 15,000 ppm ( 70, 230, or 720 mg/kg bw/d) 
for 105 weeks.  Under the conditions of the study increased incidences of non-neoplastic lesions in 
the kidney (hyperplasia), nose (inflammation, hyperplasia and metaplasia) and liver (eosinophilic 
focus) were noted. The LOAEL was the lowest average daily dose,  70 mg/kg bw/d. 
In summary, while protocols vary, results from repeated-dose testing employing 28-day to several 
100-day exposures provide results similar to those observed in the 90-day oral gavage studies, 
with NOAEL values of between 100 and 60 mg/kg bw/d. 
4.7 Toxicophores 
As demonstrated in Table 5 of the supplemental information, based on in silico predictions, the 
alkylphenols triggered the repeated dose toxicity (HESS), protein binding for chromosomal 
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aberration and oestrogen receptor (ER) binding profilers within the OECD QSAR Toolbox v3.3.5 
[34]. The alkylphenols analogues are associated with the presence of “phenols” or “substituted 
phenols” alerts, specifically with: phenols (mucous membrane irritation) Rank C, substituted 
phenols - Michael addition to the quinoid type and weak binder-OH. Additionally, the para 
substituted alkylphenols were assigned by p-alkylphenols (Hepatotoxicity) Rank A alert. ER - 
binding is also confirmed for 11 alkylphenols by the in silico nuclear receptor binding profiler [7]. 
This is not surprising as alkylphenols are associated with ER-mediated responses [35]. In 
summary, however, it is not clear how the toxicophores triggered are relevant to the endpoint 
discussed in this case study. 
4.8 Mechanistic plausibility 
Currently, there is no direct evidence for a common mechanism or mode of toxic action for mono-
alkylphenols in mammals. However, in acute aquatic exposures to fish, alkylphenols are 
considered to act via the polar narcosis mode of action [36]. Bradbury et al. [37], expanding upon 
fish acute toxicity syndromes (FATS), derived a physiological/biochemical response set for 
defining toxicity of polar narcotics. Briefly, the characteristic whole fish responses to exposure to 
model polar narcotics, including phenol and 2,4-dimethylphenol, were tremors, initiated by a 
cough, that progressed to seizures and were followed by general depression and respiratory-
cardiovascular collapse. The major changes in the respiratory-cardiovascular status upon exposure 
to polar narcotics were an increased cough frequency (in association with the seizures), and 
alterations in blood chemistry parameters attributed to the increased muscular activity causing a 
rapid shift toward anaerobic metabolism. These effects were found to be reversible and mimic the 
response to cataleptic anaesthetics [37], in which the animal passes through an excitatory phase 
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before progressing to general central nervous system depression. These finding form the basis for a 
presumptive Adverse Outcome Pathway. 
The repeated-dose data summarized in Sections 4.6.1 and 4.6.2 are consistent. 90-day repeated 
oral exposure to short-chain mono-alkylphenols at high doses (>400 mg/kg bw/ d) lead to 
behavioural effects (e.g., tremors and then lethargy). LOAEL values ( 150 mg/kg bw/d) are 
typically based on a decrease in body weight. Subsequent histopathology findings, when noted, are 
minimal and considered likely secondary to the decreased weight gains. Increased relative kidney 
and liver weights, when noted, are likely compensatory to metabolism. NOAEL values are 
typically between 50 and 100 mg/kg bw/d. These findings, and a lack of organ-specific systemic 
toxicity, are consistent with what would be expected with phenols eliciting the polar narcosis 
mode of toxic action. 
4.9 Relevant in vitro and in silico data 
Within the US EPA toxicity forecaster program (ToxCast) [38], high through-put molecular 
screening data are available for a number of alkylphenols, specifically for 16 derivatives of this 
case study. These data are summarised in Table 3, a detailed list of the assays with active results is 
given in Supplementary material - Table 4. 
Table 3. Summary of ToxCast Data for alkyl-substituted phenols 
2-methylphenol 602 (2 active) 
3-methylphenol 249 (3 active) 
4-methylphenol 602 (4 active) 
2-ethylphenol 250 (9 active) 
3-ethylphenol 249 (8 active) 
4-ethylphenol 250 (5 active) 
4-propylphenol 250 (19 active) 
2-isopropylphenol 250 (11 active) 
3-isopropylphenol 250 (10 active) 
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4-isopropylphenol 247 (18 active) 
4-butylphenol 250 (31 active) 
2-secbutylphenol 602 (12 active) 
4-secbutyphenol 603 (34 active) 
2-tertbutylphenol 602 (22 active) 
3-tertbutylphenol 250 (18 active) 
4-tertbutylphenol 600 (31 active) 
 
A trend is observed in the data reported in Table 3; generally, there is an increase in the number of 
ToxCast positive assays with the increase in size of the alkyl-chain. 
From the assay-specific results reported in Table 4 in Supplementary material, it is clear that of the 
66 different positive results only six assays are commonly activated by the majority of derivatives 
in the category. These six assays can be summated into two groups: Pregnane X receptor (PXR)-
binding and ER-binding. 
The PXR is a ligand-activated enhancer protein that is a member of the steroid/nuclear receptor 
super-family. Its primary function is to sense the presence of toxicant substances and in response 
to up-regulation of the expression of proteins involved in detoxification and clearance of these 
substances from the body [39]. PXR is activated by a large number of chemicals including 
hydroxylated ringed structures such as steroids. PXR activation induces the Phase I oxidative 
enzyme, CYP3A4 [40]. Falkner et al. noted it also upregulates the expression of Phase II 
conjugating enzymes (e.g., glutathione S-transferase) [41]. 
The oestrogen receptor (ER) is another ligand-activated enhancer protein that is a member of the 
steroid/nuclear receptor super-family. It mediates most of the biological effects of oestrogens at 
the level of gene regulation. It is an extremely well-studied receptor [42, 43]. In mammals, ER is 
encoded by two genes: alpha and beta (ERα and ERβ). Both genes function as signal transducers 
and transcription factors to modulate expression of other genes. Briefly, the oestrogen response 
elements (EREs) have highly varied affinity for hydroxylated ringed compounds (e.g., 17-
estradiol, nonylphenol). Estrodiol mimickers have been correlated with reproductive toxicity [44, 
45]. 
Neither PXR-binding nor ER-binding is considered relevant to repeated-dose toxicity as the AOP 
effect for this read across is mortality, which is not the adverse effect associated with the PXR-
binding or ER-binding. Therefore, the ToxCast data do not discredit the hypothesis that the 
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category members induce the polar narcosis mode of toxic action associated with mortality during 
a 90-day exposure regime. 
The mono-alkylphenols in Table 1 were screened with a variety of in silico profilers [7, 34]; the 
positive results can be seen in Table 5 of Supplementary material. Briefly, the evaluation of 
potential binding to the receptors is based on structural fragments and physico-chemical features 
that have been identified as essential to bind to these nuclear receptors and induce a response.  
Specifically, profilers for nuclear receptor binding were run to identify potential binding to the 
following nuclear receptors: PPARs (peroxisome proliferator-activated receptors), AR (androgen 
receptor), AHR (aryl hydrocarbon receptor), ER (oestrogen receptor), GR (glucocorticoid 
receptor), PR (progesterone receptor), FXR (farnesoid X receptor), LXR (liver X receptor), PXR 
(pregnane X receptor), THR (thyroid hormone receptor), VDR (vitamin D receptor) as well as 
RAR/RXR (retinoic acid receptor/ retinoid X receptor). Outside of ER-binding, no potential 
receptor binding was predicted. Weak ER- binding was also identified for all analogues by profiler 
within OECD QSAR Toolbox v3.3.5. Note that ToxCast also tested for all of these receptors, and 
all assays other than those related to ER- and PXR were also negative. 
Two additional profilers (protein binding for chromosomal aberration and repeated dose toxicity 
(HESS)) within OECD QSAR Toolbox were triggered by all or selected alkylphenols. The alerts 
are associated with the presence of phenol moiety and it is not clear how relevant they are to sub-
chronic repeated-dose endpoint. 
Taken collectively, the in vitro and in silico findings, which indicate no activity associated with 
specific receptors, are not inconsistent with the cited in vivo data, which indicates lethality during 
repeated oral-dose toxicity studies with short-chain mono-alkylphenols and are likely due to polar 
narcosis. Further supporting this conclusion responses observed in the repeated oral toxicity 
studies are consistent with responses associated with cataleptic anaesthetics. 
5. Statement of uncertainty 
The categorical assessments of uncertainties along with summary comments are presented in 
Tables 4 and 5. Short-chain, mono-alkylphenols are a category with acceptable data uncertainty 
and robust strengths-of-evidence for repeated-dose toxicity. Briefly, chemical similarity is high, 
and data uncertainty associated with the similarities in toxicokinetic, as well as toxicodynamic 
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profiles is low. Uncertainty associated with mechanistic relevance and completeness of the read-
across is acceptable. These simple alkylphenols are thought to be associated with the polar 
narcosis mechanisms of toxicity. This molecular mechanism is well-studied, but not well-
understood and no adverse outcome pathway is currently available. While it is unclear if oral 
repeated-dose toxicity is related to this mechanism, no evidence was found to suggest that it is not. 
Weight-of-evidence associated with the fundamentals of toxicokinetic, and toxicodynamic is high 
(i.e., this is a well-tested and well-understood group of chemicals). In terms of chemistry, the 
narrowly defined applicability domain of this category leads to all analogues or category members 
being highly similar. While there are differences among the category members with respect to 
physico-chemical properties, these differences are not considered toxicologically relevant. 
Table 4. Data uncertainty and weight-of-evidence associated with the fundamentals of chemical, 
transformation/toxicokinetic and toxicological similarity. 
 
Similarity 
Parameter 
Data 
Uncertainty a 
(empirical, modelled) 
(low, medium, high) 
Strength of 
Evidence b 
(low, medium, 
high) 
Comment 
Substance 
Identification, 
Structure and 
Chemical 
Classifications 
Low High All category members have CAS numbers. All members are 
structurally highly similar. Specifically, they: 1) belong to a 
common chemical class, phenols and the subclasses alkyl 
phenols and mono-substituted phenols 2) possess a common 
molecular scaffolding, a benzene backbone. Structurally, the 
main variables are the shape and size of the alkyl-
substituents and its position on the phenolic ring. 
Physico-
Chemical & 
Molecular 
Properties 
Empirical: 
Low 
 
Modelled: 
Low 
High All category members are appropriately similar with respect 
to key physico-chemical and molecular properties. A large 
portion of their physico-chemical properties have been 
determined experimentally and calculated values can be 
taken with high confidence. Properties values, with the 
exception of density, tread in relation to C-atom number 
within a scaffold. Specifically, all category members exhibit 
molecular weights from 100 to150 g/mol. While 
hydrophobicity (log Kow) increases with number of C-atoms 
from 2.00 to 3.50, density and pKa are constant at 1.0 
g/cm3 and 10, respectively.  Vapour pressure and water 
solubility, while influenced by position of substituted (e.g., 
para > than ortho) decrease with substituent size.  With the 
exception of 4-secbutyl and 4-tertbutyl, melting point varies 
for 12 to 50 °C. Boiling point varies for 190 to 250 °C. 
Substituents, 
Functional 
Groups, & 
Extended 
Structural 
Fragments 
Low High Substituents and functional groups are consistent across all 
category members.  Specifically, all members have common 
constituents in the form of: 1) a benzene ring, 2) single 
functional polar group, -OH, and 3) and alkyl structural 
fragments, -H, -CH3 -CH2-CH3, etc. There are no extended 
structural fragments. 
Toxicokinetics Low: High: Based on in vivo studies for multiple category members, 
31 
 
Similarity 
Parameter 
Data 
Uncertainty a 
(empirical, modelled) 
(low, medium, high) 
Strength of 
Evidence b 
(low, medium, 
high) 
Comment 
Similarity (3 source 
studies) 
 
2 additional 
studies 
there is evidence for similar toxicokinetics and metabolic 
pathways.  Specifically, small alkyl phenols are readily 
absorbed by the oral routes. The portal-of-entry metabolism 
is extensive and involves sulphate and glucuronide 
conjugations.  Once absorbed, alkyl phenols are distributed 
in the body, with levels (on a per-gram-tissue basis) in liver 
and kidney reported as being higher than in other tissues.  
Elimination from the body is rapid, primarily as sulphate and 
glucuronide conjugates in the urine. Alkyl phenols do not 
appear to accumulate significantly in the body. 
In vivo 
Toxicodynamic 
Similarity 
Empirical: 
In vivo: Low 
(5 source 
substances) 
High: 
9 additional 
studies 
Based on in vivo studies for multiple category members, 
there is evidence for similar repeated-dose toxicodynamics. 
Specifically, at higher doses 90-day repeated oral gavage 
exposure result displays of lethargy, tremors, etc. Dose-
dependent body weight decrease is observed at intermediate 
doses. Histopathology findings, when noted, were minimal 
and considered likely secondary to the decreased weight 
gains. Increased relative kidney and liver weights, when 
noted, are likely compensatory to metabolism. 
Toxicophores 
/Mechanistic 
alerts 
Low Medium Based on in silico profilers, no category member contains 
any established toxicophores other than polar narcosis or 
ER-binding. 
Mechanistic 
plausibility and 
AOP-Related 
Events 
Low-to-
Medium- 
Low-to-
Medium 
No AOP is currently available for the hypothesized mode of 
action, polar narcosis; in vivo data is not inconsistent with 
the proposed mode of action. 
Relevant in 
vitro and in 
silico endpoints 
Low Medium In vitro data in the form of ToxCast and in silico data in the 
form of screening profilers finds little outside of ER-binding 
affinity to be common among the category members. 
 
Overall uncertainty in similarity of category members is low. 
 
Summary: Key features of chemistry are similar within the category.  Key features of toxicokinetics and 
metabolism are generally common within the category.  Key features of toxicodynamics are generally common 
within the category.  Positive features of mechanistically similarity? are generally lacking.  
a Uncertainty associated with underlying information/data used in the exercise 
b Consistency within the information/data used to support the similarity rational and prediction 
 
From a toxicokinetic standpoint, data for 2-methyl- and 3-methyl-phenol, as well as 4-
tertbutylphenol is supplemented with data for a mixture of 3- and 4-methylphenol, as well as 
phenol and 2-isopropl-5-methylphenol. All substances are readily absorbed orally, metabolised via 
phase II conjugations and eliminated rapidly in the urine. 
From a toxicodynamic standpoint, the experimental 90-day oral gavage data for 2-methyl-, 3-
methyl- and 4-methylphenol is supplemented by other experimental repeated dose data. Included 
in this are data for 4-tertbutylphenol, 2-secbutylphenol 2-tertbutylphenol, a mixture of 3- and 4-
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methylphenol, mixture of 2-, 3-, and 4-ethylphenols, as well as a mixture of various isomers of 
xylenols. Collectively these data suggest that all category members are toxicodynamically similar, 
both qualitatively (symptomology) and quantitatively (potency). 
The major source of uncertainty for this group of alkylphenols is associated with mechanistic 
plausibility. There is no adverse outcome pathway related to repeated-dose toxicity associated with 
this category. 
 
Table 5. Assessment of uncertainty associated with mechanistic relevance and completeness of the 
read-across. 
 
Factor Uncertainty or WoE 
(low, medium, high) 
Comment 
The problem and 
premise of the read-
across 
Medium The endpoint to be read across, oral gavage sub-chronic 
repeated-dose toxicity, for mono-alkylphenols is moderately 
well-studied but not well-understood. 
In vivo data read across 
Number of analogues 
in the source set 
Low; 6 of 24 tested There are several suitable members in each of the two sub-
categories with in vivo apical endpoint data usable for read-
across. 
Quality of the in vivo 
apical endpoint data 
read across 
Low; consistent LOAEL 
symptoms; similar 
NOAEL potency; several 
supporting studies  
High quality empirical data from TG 408 for the stated 
regulatory endpoint are available. Additional in vivo data 
(i.e., TG 407 and TG 422) exist for other alkyl-substituted 
phenols.  
Severity of the apical 
in vivo hazard 
Low-to-Medium; The 
most common reported 
NOAEL value is 50 
mg/kg bw/d.  
Typically, gavage exposure scheme leads to high potency 
that exposure via fed or drinking. 
Evidence to the biological argument for RA 
Robustness of 
analogue data set 
Low; The in vivo 
repeated-dose toxicity 
data is adequate. The in 
vitro and in silico data 
for alkyl-substituted 
phenols is consistent. 
The in vivo studies were judged to be reliable and conducted 
under the appropriate conditions.  Relevant in vitro data is 
limited. 
Concordance with 
regard to the 
intermediate and 
apical effects and 
potency data 
Medium to High; 
intermediate effects data 
are very limited. 
Since there is no toxicity pathway for alkylphenols 
repeated-dose effects, there are no true intermediate events.  
Without relevant in vitro data, concordance between events 
cannot be ascertained.  
Weight-of-Evidence 
(WoE) 
High Overall the available information and data is generally 
consistent with the stated premise. The structural limitations 
of the category strengthen the WoE. Having multiple 
sources of toxicokinetics data strengthens the WoE. Having 
multiple sources of in vivo data adds to the WoE. The only 
consistent results from ToxCast, and receptor binding 
screening (i.e., ER- and PXR-related activity, does not 
appear to be related to repeated-dose toxicity and therefore 
has no impact on WoE. 
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The overall uncertainty associated with this read-across prediction is judged to be medium largely due to 
mechanistic uncertainty. 
6. Conclusions 
In vivo oral repeated-dose exposure to alkyl-substituted phenols gives rise to a variety of toxicity 
symptoms which are dose dependent. At high doses (>400 mg/kg bw/ d) behavioural effects (e.g., 
lethargy, tremors, etc.) are observed LOAEL values in the range of 75 to 175 mg/kg bw/d are 
typically based on a decrease in body weight. Adverse effects associated with liver and/or kidney 
are not physiologically significant and considered secondary to the decreased weight gains and 
likely compensatory in nature. A NOAEL value of 50 mg/kg bw/d may be read across to fill data 
gaps for the other derivatives in the category. 
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Supplementary Material 
Read-Across of 90-Day Rat Oral Repeated-Dose Toxicity: A Case Study for Selected mono-alkylphenols  
 
Tables for Assessing Similarity of Analogues and Category Members for Read-Across 
Table 1: Comparison of Substance Identification, Structure and Chemical Classifications 
 
ID Name CAS No: SMILES 2D Structure 
Molecular 
Formula 
Molecular 
Weight 
[g/mol] 
1 2-methylphenol 95-48-7 Cc1ccccc1O 
 
C7H8O 108 
2 3-methylphenol 108-39-4 Cc1cccc(O)c1 
 
C7H8O 108 
3 4-methylphenol 106-44-5 Cc1ccc(O)cc1 
 
C7H8O 108 
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ID Name CAS No: SMILES 2D Structure 
Molecular 
Formula 
Molecular 
Weight 
[g/mol] 
4 2-ethylphenol 90-00-6 CCc1ccccc1O 
 
C8H10O 122 
5 3-ethylphenol 620-17-7 CCc1cccc(O)c1 
 
C8H10O 122 
6 4-ethylphenol 123-07-9 CCc1ccc(O)cc1 
 
C8H10O 122 
7 2-propylphenol 644-35-9 CCCc1ccccc1O 
 
C9H12O 136 
8 3-propylphenol 621-27-2 CCCc1cccc(O)c1 
 
C9H12O 136 
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ID Name CAS No: SMILES 2D Structure 
Molecular 
Formula 
Molecular 
Weight 
[g/mol] 
9 4-propylphenol 645-56-7 CCCc1ccc(O)cc1 
 
C9H12O 136 
10 2-isopropylphenol 88-69-7 c1(c(cccc1)O)C(C)C 
 
C9H12O 136 
11 3-isopropylphenol 618-45-1 CC(C)c1cccc(O)c1 
 
C9H12O 136 
12 4-isopropylphenol 99-89-8 CC(C)c1ccc(O)cc1 
 
C9H12O 136 
13 2-butylphenol 3180-09-4 CCCCc1ccccc1O 
 
C10H14O 150 
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ID Name CAS No: SMILES 2D Structure 
Molecular 
Formula 
Molecular 
Weight 
[g/mol] 
14 3-butylphenol 28805-86-9 CCCCc1cccc(c1)O 
 
C10H14O 150 
15 4-butylphenol 1638-22-8 CCCCc1ccc(O)cc1 
 
C10H14O 150 
16 2-isobutylphenol 4167-75-3 CC(C)Cc1ccccc1O 
 
C10H14O 150 
17 3-isobutylphenol 30749-25-8 CC(C)Cc1cccc(O)c1 
 
C10H14O 150 
H
3
C
HO
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ID Name CAS No: SMILES 2D Structure 
Molecular 
Formula 
Molecular 
Weight 
[g/mol] 
18 4-isobutylphenol 4167-74-2 CC(C)Cc1ccc(O)cc1 
 
C10H14O 150 
19 2-secbutylphenol 89-72-5 CCC(C)c1ccccc1O 
 
C10H14O 150 
20 3-secbutylphenol 3522-86-9 CCC(C)c1cccc(O)c1 
 
C10H14O 150 
21 4-secbutyphenol 99-71-8 CCC(C)c1ccc(O)cc1 C10H14O 150 
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ID Name CAS No: SMILES 2D Structure 
Molecular 
Formula 
Molecular 
Weight 
[g/mol] 
22 2-tertbutylphenol 88-18-6 CC(C)(C)c1ccccc1O 
 
C10H14O 150 
23 3-tertbutylphenol 585-34-2 CC(C)(C)c1cccc(c1)O 
 
C10H14O 150 
24 4-tertbutylphenol 98-54-4 CC(C)(C)c1ccc(cc1)O 
 
C10H14O 150 
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Table 2: Comparison of Physico-Chemical and Molecular Properties1 
 
ID Name 
Molecular Weight 
[g/mol] 
Log 
Kow 
Vapor Pressure  
[Pa at 25°C ] 
Densityc 
[g/cm3] 
Melting 
Point [°C] 
Water 
Solubility 
[mg/L] 
Boiling 
Point 
[°C] 
pKa 
1 2-methylphenol 108 1.95a 33.40 1.14 31 9066 191 10.3 
2 3-methylphenol 108 1.96a 22.3 1.04 12 8890 201 10.1 
3 4-methylphenol 108 1.94a 16.60 1 15.96 9246 191 10.3 
4 2-ethylphenol 122 2.47a 19.7 1 18 2912 205 10.2d 
5 3-ethylphenol 122 2.4a 9.15 1 27.13 3342 211 9.9d 
6 4-ethylphenol 122 2.58a 5.17 1 27.13 4900 211 10e 
7 2-propylphenol 136 2.93a 8.37 1 38.3 1039 230 10.5f 
8 3-propylphenol 136 3.04 4.9 1 26 1669 228 10.1f 
9 4-propylphenol 136 3.2b 4.13 1 22 1280 233 10.3f 
10 2-isopropylphenol 136 2.88a 12 1 15.5 1146 214 10.5f 
11 3-isopropylphenol 136 2.97 4.9 1 26 962.3 228 10.2f 
12 4-isopropylphenol 136 2.9a 2.01 1 27.49 1102 230 10.2f 
13 2-butylphenol 150 3.53 0.027 1 49.21 276.4 235 10.6 
14 3-butylphenol 150 3.27a 5.35 1 16 464.0 228 10.6 
15 4-butylphenol 150 3.65a 1.17 1 22 219.8 248 10.1 
16 2-isobutylphenol 150 3.46 2.31 1 38.56 319.4 237 10.2 
17 3-isobutylphenol 150 3.46 2.31 1 38.56 319.4 237 10.0 
18 4-isobutylphenol 150 3.46 2.31 1 38.56 319.4 237 9.8 
19 2-secbutylphenol 150 3.27a 5.35 0.98 38.56 464 237 10.4 
20 3-secbutylphenol 150 3.46 2.13 1 38.56 319.4 237 10.0 
21 4-secbutyphenol 150 3.08a 1.12 1 22 674.2 241 10.1 
22 2-tertbutylphenol 150 3.31a 0.98 1 36.91 428.9 223 10.3g 
23 3-tertbutylphenol 150 3.3b 1.8 1 42.3 437.4 240 10.1 
24 4-tertbutylphenol 150 3.3 0.00447 1 36.91 580.0 237 10.4 
47 
 
1Values typically derived from EPISuite v4.1 experimental values where taken over predicted when available; a Hansch, C et al. (1995), b Sangster 
(1993), c ACD/Lab Percepta Platform - PhysChem Module (from ChemSpider), d Pearce,P.J. & Simkins,R.J.J. (1968), e Schultz,T.W. (1987A), f 
Serjeant,E.P. & Dempsey,B. (1979), g Schueuerman,G. (1991). 
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Table 3: Comparison of Substituents, Functional Groups, and Extended Structural Fragments. 
 
ID Name Key Substituent(s) Functional Group(s) Chemical Class: 
1 2-methylphenol phenol (C6H12O) Alcohol, olefinic attach 
[-OH] 
Aliphatic Carbon [CH3] Aromatic Carbon [C]  alkyl phenols 
2 3-methylphenol phenol (C6H12O) Alcohol, olefinic attach 
[-OH] 
Aliphatic Carbon [CH3] Aromatic Carbon [C]  alkyl phenols 
3 4-methylphenol phenol (C6H12O) Alcohol, olefinic attach 
[-OH] 
Aliphatic Carbon [CH3] Aromatic Carbon [C]  alkyl phenols 
4 2-ethylphenol phenol (C6H12O) Alcohol, olefinic attach 
[-OH] 
Aliphatic Carbon [CH2] 
[CH3] 
Aromatic Carbon [C]  alkyl phenols 
5 3-ethylphenol phenol (C6H12O) Alcohol, olefinic attach 
[-OH] 
Aliphatic Carbon [CH2] 
[CH3] 
Aromatic Carbon [C]  alkyl phenols 
6 4-ethylphenol phenol (C6H12O) Alcohol, olefinic attach 
[-OH] 
Aliphatic Carbon [CH2] 
[CH3] 
Aromatic Carbon [C]  alkyl phenols 
7 2-propylphenol phenol (C6H12O) Alcohol, olefinic attach 
[-OH] 
Aliphatic Carbon [CH] 
[CH2] [CH3] 
Aromatic Carbon [C]  alkyl phenols 
8 3-propylphenol phenol (C6H12O) Alcohol, olefinic attach 
[-OH] 
Aliphatic Carbon 
[CH][CH2] [CH3] 
Aromatic Carbon [C]  alkyl phenols 
9 4-propylphenol phenol (C6H12O) Alcohol, olefinic attach 
[-OH] 
Aliphatic Carbon 
[CH][CH2] [CH3] 
Aromatic Carbon [C]  alkyl phenols 
10 2-isopropylphenol phenol (C6H12O) Alcohol, olefinic attach 
[-OH] 
Aliphatic Carbon [CH] 
[CH3] 
Aromatic Carbon [C] Tertiary Carbon alkyl phenols 
11 3-isopropylphenol phenol (C6H12O) Alcohol, olefinic attach 
[-OH] 
Aliphatic Carbon [CH] 
[CH3] 
Aromatic Carbon [C] Tertiary Carbon alkyl phenols 
12 4-isopropylphenol phenol (C6H12O) Alcohol, olefinic attach 
[-OH] 
Aliphatic Carbon [CH] [-
CH3] 
Aromatic Carbon [C] Tertiary Carbon alkyl phenols 
13 2-butylphenol phenol (C6H12O) Alcohol, olefinic attach 
[-OH] 
Aliphatic Carbon 
[CH][CH2] [CH3] 
Aromatic Carbon [C]  alkyl phenols 
14 3-butylphenol phenol (C6H12O) Alcohol, olefinic attach 
[-OH] 
Aliphatic Carbon 
[CH][CH2] [CH3] 
Aromatic Carbon [C]  alkyl phenols 
15 4-butylphenol phenol (C6H12O) Alcohol, olefinic attach 
[-OH] 
Aliphatic Carbon 
[CH][CH2] [CH3] 
Aromatic Carbon [C]  alkyl phenols 
16 2-isobutylphenol phenol (C6H12O) Alcohol, olefinic attach 
[-OH] 
Aliphatic Carbon 
[CH][CH2] [CH3] 
Aromatic Carbon [C] Tertiary Carbon alkyl phenols 
17 3-isobutylphenol phenol (C6H12O) Alcohol, olefinic attach 
[-OH] 
Aliphatic Carbon 
[CH][CH2] -CH3] 
Aromatic Carbon [C] Tertiary Carbon alkyl phenols 
18 4-isobutylphenol phenol (C6H12O) Alcohol, olefinic attach 
[-OH] 
Aliphatic Carbon [CH][-
CH2-] [-CH3] 
Aromatic Carbon [C] Tertiary Carbon alkyl phenols 
19 2-secbutylphenol phenol (C6H12O) Alcohol, olefinic attach 
[-OH] 
Aliphatic Carbon 
[CH][CH2] [CH3] 
Aromatic Carbon [C] Tertiary Carbon alkyl phenols 
20 3-secbutylphenol phenol (C6H12O) Alcohol, olefinic attach Aliphatic Carbon Aromatic Carbon [C] Tertiary Carbon alkyl phenols 
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[-OH] [CH][CH2] [CH3] 
21 4-secbutyphenol phenol (C6H12O) Alcohol, olefinic attach 
[-OH] 
Aliphatic Carbon 
[CH][CH2] [CH3] 
Aromatic Carbon [C] Tertiary Carbon alkyl phenols 
22 2-tertbutylphenol phenol (C6H12O) Alcohol, olefinic attach 
[-OH] 
Aliphatic Carbon [CH][C] 
[CH3] 
Aromatic Carbon [C] Tertiary Carbon alkyl phenols 
23 3-tertbutylphenol phenol (C6H12O) Alcohol, olefinic attach 
[-OH] 
Aliphatic Carbon [CH][C] 
[CH3] 
Aromatic Carbon [C] Tertiary Carbon alkyl phenols 
24 4-tertbutylphenol phenol (C6H12O) Alcohol, olefinic attach 
[-OH] 
Aliphatic Carbon [CH][C] 
[CH3] 
Aromatic Carbon [C] Tertiary Carbon alkyl phenols 
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Table 4: Toxcast assay active results for derivatives. 
                                                              Name 
 
 
Toxcast assay 
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ACEA_T47D_80hr_Negative * * * * * * * * * * 68.8 * 54.7 * * * 
ACEA_T47D_80hr_Positive * 71.7 * * * * 64.8 * * 20.7 7.19 * 9.68 * * * 
ATG_Ahr_CIS * * * 17.8 * * * * * * * * * * * * 
ATG_Ahr_CIS_perc * * * 17.8 * * * * * * * * * * * * 
ATG_AP_1_CIS 112 * * * * * * * * * * * * * * * 
ATG_AP_1_CIS_perc 112 * * * * * * * * * * * * * * * 
ATG_BRE_CIS * * * * * * * * * * * * 96.5 * * * 
ATG_BRE_CIS_perc * * * * * * * * * * * * 96.5 * * * 
ATG_CMV_CIS * * * * * * * * * * 79.6 * 86.5 * * * 
ATG_CMV_CIS_perc * * * * * * * * * * 79.6 * 86.5 * * * 
ATG_CRE_CIS * * * * * * * * * * * * * 52.4 * * 
ATG_CRE_CIS_perc * * * * * * * * * * * * * 52.4 * * 
ATG_ERa_TRANS * * 40 * 153 86 14.5 114 89 28.2 6.81 68.3 8.19 24.5 24.4 7.66 
ATG_ERa_TRANS_perc * * 8.14 * 144 62.7 11.2 111 61 22.3 4.91 28.6 3.82 17.8 12.3 2.37 
ATG_ERE_CIS * * * * * * * * * * 11.5 * 4.76 * * 5.78 
ATG_ERE_CIS_perc * * * * * * * * * * 7.73 * 3.27 * * 3.65 
ATG_HSE_CIS * * * * * * * * * * 116 * * * * * 
ATG_HSE_CIS_perc * * * * * * * * * * 116 * * * * * 
ATG_MRE_CIS * * * * * * * * * * * * * 120 * 149 
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ATG_MRE_CIS_perc * * * * * * * * * * * * * 120 * 149 
ATG_NRF2_ARE_CIS * * * 39.2 * * 32.5 * * 62 90.9 73.4 87.8 * * 104 
ATG_NRF2_ARE_CIS_perc * * * 39.2 * * 32.5 * * 62 90.9 73.4 87.8 * * 104 
ATG_NURR1_TRANS * * * * * * * * * * * * * 60.2 * * 
ATG_NURR1_TRANS_perc * * * * * * * * * * * * * 60.2 * * 
ATG_PPARa_TRANS * * * * * * * * * * * * 11.6 * * * 
ATG_PPARa_TRANS_perc * * * * * * * * * * * * 11.6 * * * 
ATG_PPARg_TRANS * * * * * * * * * * 78.1 * 70.9 * * * 
ATG_PPARg_TRANS_perc * * * * * * * * * * 78.1 * 70.9 * * * 
ATG_PXR_TRANS * * * 18.7 * * 26.1 * 53 29.4 83.1 35.1 26.8 26.1 29.2 17.4 
ATG_PXR_TRANS_perc * * * 18.7 * * 26.1 * 53 29.4 83.1 35.1 26.8 26.1 29.2 17.4 
ATG_PXRE_CIS * * * 25.6 44.9 * 37.4 99.9 22.2 * * 35.1 33.1 27.7 29.4 27.3 
ATG_PXRE_CIS_perc * * * 25.6 44.9 * 37.4 99.9 22.2 * * 35.1 33.1 27.7 29.4 27.3 
ATG_RORb_TRANS * * * * * * * * * * * * 16.2 * * * 
ATG_RORb_TRANS_perc * * * * * * * * * * * * 16.2 * * * 
ATG_RXRb_TRANS * * * * * * 41.4 94.6 * 84.3 87.7 * 49.9 26.6 96.4 * 
ATG_RXRb_TRANS_perc * * * * * * 41.4 94.6 * 84.3 87.7 * 49.9 26.6 96.4 * 
ATG_VDRE_CIS * * * * * * * * * * * 101 * * * 23.6 
ATG_VDRE_CIS_perc * * * * * * * * * * * 101 * * * 23.6 
NVS_GPCR_hV1A * NA 22.5 NA NA NA NA NA NA NA NA * * * NA * 
NVS_MP_rPBR * * * * 36.1 * * * * * * * * * * * 
NVS_NR_rMR * * * * * 10.6 * * * * * * * * * * 
NVS_TR_hNET * NA * NA NA NA NA NA NA NA NA * 10.3 * NA * 
OT_ER_ERaERa_0480 * * * * * * 47.1 * * 35.2 15.2 * 37.3 * 44.2 40.4 
OT_ER_ERaERa_1440 * * * * * * * * * * 17.3 * 48.2 * * 40 
OT_ER_ERaERb_0480 * * * * * 44.5 37.2 * 38.4 40.5 11.5 * 32 * 36.7 26.4 
OT_ER_ERaERb_1440 * * * * * * 41 * * 46.4 14 * 33.9 * 45.7 24 
OT_ER_ERbERb_0480 * * * * * * 35.4 * 44 43.7 11.2 * 15.3 41.9 38.1 23.8 
OT_ER_ERbERb_1440 * * * * * * 39.5 * 35.3 41.1 14 * 28.4 * 41.5 18.6 
OT_ERa_EREGFP_0120 * * * * * * * * * * * * 10.3 * * 10.6 
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OT_ERa_EREGFP_0480 * * * * * * * * * * * * 18.7 * * 11.1 
OT_NURR1_NURR1RXRa_0480 * * * * * * * * * * 68.2 * * * * * 
OT_SRC1_SRC1FXR_0480 * * * * * * * * * * * * * * 48.5 * 
OT_SRC1_SRC1FXR_1440 * * 63.7 * * * * * * * * * * * 34.2 * 
Tox21_AhR_viability * * * * * * * 50.9 * 0.001 * * * * * * 
Tox21_AR_BLA_Agonist_ch1 * 0.017 * * * * * * * * * * * * * 0.002 
Tox21_AR_LUC_MDAKB2_Antagonist_viability * * * * * * * 22.9 * * * * * 66.3 * 59.6 
Tox21_Aromatase_Inhibition * * * * * * * * * * 38.9 * * * * * 
Tox21_Aromatase_Inhibition_viability * * * * * * * 53.4 * 0.641 * * * 10.6 * 39.5 
Tox21_ELG1_LUC_Agonist_viability * * * * 22.7 * * * * * * * * * * * 
Tox21_ERa_BLA_Agonist_ch2 * * * * * * * * * * * * * 48.9 * 47.6 
Tox21_ERa_BLA_Agonist_ratio * * * * 0.13 * * * * * * * * 51.6 * 45.4 
Tox21_ERa_LUC_BG1_Antagonist_viability * * * * * * * * * 0.001 * * * * * * 
Tox21_MitochondrialToxicity_ratio * * * * * * 42.6 * * * 44.2 37.3 28.4 50.2 40.5 25.4 
Tox21_MitochondrialToxicity_rhodamine * * * * * * 43.8 * * * 45.7 49.3 29.6 50.4 41.9 24.5 
Tox21_PPARg_BLA_Agonist_ch1 * * * * * * * * * * * * * * * 1E-03 
Tox21_TR_LUC_GH3_Antagonist_viability * * * * * * * 9.59 * * 58.7 * * 12.5 * 12.9 
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Table 5: Comparison of Toxicophores. 
 
 
ID Name 
Protein binding for 
chromosomal 
aberration by 
OECD1 
Repeated dose toxicity 
(HESS) by OECD1 
Oestrogen Receptor 
binding by OECD1 
Nuclear receptor 
binding2 
1 2-methylphenol Substituted Phenols Phenols (Mucous membrane 
irritation) Rank C 
Weak binder, OH 
No alert 
2 3-methylphenol Substituted Phenols Phenols (Mucous membrane 
irritation) Rank C 
Weak binder, OH No alert 
3 4-methylphenol Substituted Phenols Phenols (Mucous membrane 
irritation) Rank C 
p-Alkylphenols 
(Hepatotoxicity) Rank A 
Weak binder, OH No alert 
4 2-ethylphenol Substituted Phenols Phenols (Mucous membrane 
irritation) Rank C 
Weak binder, OH No alert 
5 3-ethylphenol Substituted Phenols Phenols (Mucous membrane 
irritation) Rank C 
Weak binder, OH No alert 
6 4-ethylphenol Substituted Phenols Phenols (Mucous membrane 
irritation) Rank C 
p-Alkylphenols 
(Hepatotoxicity) Rank A 
Weak binder, OH No alert 
7 2-propylphenol Substituted Phenols Phenols (Mucous membrane 
irritation) Rank C 
Weak binder, OH No alert 
8 3-propylphenol Substituted Phenols Phenols (Mucous membrane 
irritation) Rank C 
Weak binder, OH No alert 
9 4-propylphenol Substituted Phenols Phenols (Mucous membrane 
irritation) Rank C 
p-Alkylphenols 
(Hepatotoxicity) Rank A 
Weak binder, OH No alert 
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ID Name 
Protein binding for 
chromosomal 
aberration by 
OECD1 
Repeated dose toxicity 
(HESS) by OECD1 
Oestrogen Receptor 
binding by OECD1 
Nuclear receptor 
binding2 
10 2-isopropylphenol Substituted Phenols Phenols (Mucous membrane 
irritation) Rank C 
Weak binder, OH No alert 
11 3-isopropylphenol Substituted Phenols Phenols (Mucous membrane 
irritation) Rank C 
Weak binder, OH No alert 
12 4-isopropylphenol Substituted Phenols Phenols (Mucous membrane 
irritation) Rank C 
p-Alkylphenols 
(Hepatotoxicity) Rank A 
Weak binder, OH No alert 
13 2-butylphenol Substituted Phenols Phenols (Mucous membrane 
irritation) Rank C 
Weak binder, OH No alert 
14 3-butylphenol Substituted Phenols Phenols (Mucous membrane 
irritation) Rank C 
Weak binder, OH 
ER 
15 4-butylphenol Substituted Phenols Phenols (Mucous membrane 
irritation) Rank C 
p-Alkylphenols 
(Hepatotoxicity) Rank A 
Weak binder, OH 
ER 
16 2-isobutylphenol Substituted Phenols Phenols (Mucous membrane 
irritation) Rank C 
Weak binder, OH 
ER 
17 3-isobutylphenol Substituted Phenols Phenols (Mucous membrane 
irritation) Rank C 
Weak binder, OH 
ER 
18 4-isobutylphenol Substituted Phenols Phenols (Mucous membrane 
irritation) Rank C 
p-Alkylphenols 
(Hepatotoxicity) Rank A 
Weak binder, OH 
ER 
19 2-secbutylphenol Substituted Phenols Phenols (Mucous membrane 
irritation) Rank C 
Weak binder, OH 
ER 
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ID Name 
Protein binding for 
chromosomal 
aberration by 
OECD1 
Repeated dose toxicity 
(HESS) by OECD1 
Oestrogen Receptor 
binding by OECD1 
Nuclear receptor 
binding2 
20 3-secbutylphenol Substituted Phenols Phenols (Mucous membrane 
irritation) Rank C 
Weak binder, OH 
ER 
21 4-secbutyphenol Substituted Phenols Phenols (Mucous membrane 
irritation) Rank C 
p-Alkylphenols 
(Hepatotoxicity) Rank A 
Weak binder, OH 
ER 
22 2-tertbutylphenol No alert Phenols (Mucous membrane 
irritation) Rank C 
Weak binder, OH 
ER 
23 3-tertbutylphenol Substituted Phenols Phenols (Mucous membrane 
irritation) Rank C 
Weak binder, OH 
ER 
24 4-tertbutylphenol Substituted Phenols Phenols (Mucous membrane 
irritation) Rank C 
p-Alkylphenols 
(Hepatotoxicity) Rank A 
Weak binder, OH 
ER 
1 OECD QSAR Toolbox 3.3. 2 COSMOS profilers available via COSMOS space: http://cosmosspace.cosmostox.eu 
 
 
 
 
